Figure 2 C1q/tumor necrosis factor-related protein 13 (CTRP13) suppressed oxidized low-density lipoprotein (ox-LDL)-induced human umbilical vein endothelial cell (HUVEC) ferroptosis. (A) Quantification of HUVEC viability following different doses of CTRP13 treatment. (B) Quantification of HUVEC viability following different doses of CTRP13 treatment following co-incubation with or without ox-LDL 100 μg/mL. (C–E) Acyl-CoA synthetase long-chain family member 4 (ACSL4), glutathione peroxidase 4 (GPX4), and recombinant solute carrier family 7, member 11 (SLC7A11) mRNA expressions. (F) Protein expression levels were measured using Western blot analysis. The following groups were assessed: Control; ox-LDL; ox-LDL+CTRP13150 ng/mL; ox-LDL+CTRP13 300 ng/mL; ox-LDL+CTRP13 450 ng/mL); ox-LDL+Fer-1, HUVECs were pre-treated with ox-LDL 100 μg/mL. (G–I) Quantitative analysis of ferroptosis-associated protein expression. The data are expressed as the mean±SD (n=3–4 per group). Statistical power=0.953772, effect size(r)=0.858954. * P<0.05 vs the control group. # P<0.05 vs the ox-LDL group. The relative protein levels were quantified by Image J software (NIH, Bethesda, MD, USA). GraphPad Prism 9.0 software (La Jolla, USA) was used to analyze the data.